Cardiovascular Inflammation Reduction Trial - Inflammation Imaging Study

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 123 participants.

Also called NCT02576067

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 123 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02576067
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02576067. Randomized; double masking; primary purpose treatment. Start 2015-12-18 (actual); primary completion 2019-03-29 (actual). Results posted on 2020-04-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Cardiovascular Inflammation Reduction Trial - Inflammation Imaging Study
Acronym
CIRT
Condition
Vascular Inflammation
Condition
Atherosclerotic Cardiovascular Disease
Intervention (Drug)
Low dose methotrexate
Intervention (Drug)
Placebo
Lead sponsor
Icahn School of Medicine at Mount Sinai (class: other)
Collaborator
Brigham and Women's Hospital (class: other)
Collaborator
Massachusetts General Hospital (class: other)
Collaborator
Unity Health Toronto (class: other)
Collaborator
National Institutes of Health (NIH) (class: US National Institutes of Health)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct02576067
Content hash
921376d7d97a2316b2f435d442a0391a94a4dec81cbf41218b7fd6e96823ae19